middle.news
Bubs Australia Posts $2.9m EBITDA Turnaround, Eyes FDA Approval in 2025
8:48am on Wednesday 22nd of January, 2025 AEDT
•
Food & Beverage
Read Story
Bubs Australia Posts $2.9m EBITDA Turnaround, Eyes FDA Approval in 2025
8:48am on Wednesday 22nd of January, 2025 AEDT
Key Points
H1 FY25 positive EBITDA of $2.9 million, reversing prior year losses
Q2 FY25 gross revenue up 42% year-on-year to $32.9 million
Strong regional growth: USA revenue +26%, China +68%, Australia +32%
FDA clinical trial enrolment completed; approval expected October 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bubs Australia (ASX:BUB)
OPEN ARTICLE